Two decades of medtech finance mastery, and today it reports for duty in San Diego. Micah Young’s first day as QuidelOrtho’s CFO is July 6, and the SoCal life sciences corridor just got another proof point that its best talent stays home.
When QuidelOrtho announced the appointment of Micah Young as chief financial officer on June 23, 2026, effective July 6, the global diagnostics leader welcomed one of Southern California’s most accomplished medtech finance executives. Young arrives from Irvine-based Masimo, where he served as executive vice president and CFO after joining as finance chief in 2017, helping lead the company through strategic transformation, operational improvement, disciplined capital allocation, and significant transaction activity. His earlier chapters include progressively senior finance roles at NuVasive, finance and accounting roles at Zimmer Holdings, and a career start at Deloitte. He succeeds Joseph Busky, who announced his retirement and graciously stays on in an advisory role to support a smooth transition.
“I am honored to join QuidelOrtho at an important point in the Company’s evolution. QuidelOrtho has a strong global portfolio, a meaningful mission and clear opportunities to enhance execution and performance. I look forward to working with Brian, the Board and the leadership team to strengthen operational discipline, support growth and create sustainable value for shareholders, customers and patients.”
Micah Young, Chief Financial Officer, QuidelOrtho
President and CEO Brian Blaser called Young an accomplished public-company CFO with deep medical technology expertise and a strong track record of improving financial performance and strengthening cash flow. Notice the last word of Young’s own quote: patients. Diagnostics is a mission business, and the best finance leaders in this sector never lose sight of who the balance sheet ultimately serves.
The regional story here is one of our favorites to tell. Irvine to San Diego, Masimo to QuidelOrtho: Southern California’s life sciences corridor keeps its elite talent circulating inside the ecosystem, compounding domain knowledge with every move. That is the mark of a mature talent market, the kind we map in the SoCal talent brief, where the bench is deep enough that world-class companies can fill their most important seats without ever leaving the region.
For rising finance leaders in SoCal medtech, Young’s path is the playbook: Big Four foundation, deep operating years inside device companies, then the CFO chair, then the bigger CFO chair. Every stop added a capability, and the region rewarded each one, a pattern straight out of why CFOs are the new CEOs. And a warm salute to Joseph Busky, whose leadership through QuidelOrtho’s formative merger years and generous transition support show exactly how a finance chief finishes strong.
QuidelOrtho itself gives him a global canvas. With expertise spanning clinical chemistry, immunoassay, immunohematology, and molecular testing, the company’s diagnostics reach from the point of care to hospital labs on every continent, and its San Diego headquarters anchors one of the deepest life sciences talent pools in the world. A finance chief with Young’s operating range arriving at a platform with that mission and that footprint is the kind of pairing that lifts both, and the region gets to watch it compound from the front row.
To Micah Young: congratulations. Two decades of preparation, one mission-driven mandate, and a corridor full of colleagues cheering you south on the 5. Go build.
Know a leader who deserves this spotlight?
This is what we do at Recruiter Hustle: we don’t just report the move, we honor the person behind it. If you, your company, or someone you admire just stepped into a new chapter, we want to tell that story right.
→ Submit a People Move • or reach out to Cathy Trinh directly, and let’s put your name in the light.
HEART. HUMAN. HUSTLE.
Sources & verification
Appointment & quotes: QuidelOrtho press release (SEC Exhibit 99.1), June 23, 2026, effective July 6, 2026

